Thrombosis on a Mechanical Aortic Valve whilst Anti-coagulated With Dabigatran

Heart Lung and Circulation

Volumn 21, Issue 1, 2012, Pages 53-55

  Stewart, Ralph A H ^a   Astell, Heather ^a   Young, Laura ^a   White, Harvey D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Anticoagulation; Dabigatran; Prosthetic heart valves

Indexed keywords

ACETYLSALICYLIC ACID; DABIGATRAN ETEXILATE; PHENINDIONE; WARFARIN;

ADULT; AORTA VALVE REPLACEMENT; ARM WEAKNESS; ARTICLE; BRAIN INFARCTION; CASE REPORT; DIFFUSION WEIGHTED IMAGING; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; HEADACHE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; SAINT JUDE HEART VALVE PROSTHESIS; THROMBOEMBOLISM; THROMBOPLASTIN TIME; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

AORTIC VALVE; AORTIC VALVE STENOSIS; BENZIMIDAZOLES; BETA-ALANINE; BLOOD COAGULATION; DRUG RESISTANCE; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FIBRINOLYTIC AGENTS; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; INTRACRANIAL EMBOLISM; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RISK ADJUSTMENT; SEVERITY OF ILLNESS INDEX; THROMBOSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84855851690     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2011.08.014     Document Type: Article

References (8)

1. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
2. Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
3. Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
4. Bonow R.O., Carabello B.A., Chatterjee K., de Leon A.C., Faxon D.P., Freed M.D., et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008, 118:e523-e661.
5. Koertke H., Zittermann A., Tenderich G., Wagner O., El Arousy M., Krian A., et al. Low-dose oral anticoagulation in patients with mechanical heart valve prostheses: final report from the early self-management anticoagulation trial II. Eur Heart J 2007, 28:2479-2484.
6. van Ryn J., Stangier J., Haertter S., Liesenfeld K.H., Wienen W., Feuring M., et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010, 103:1116-1127.
7. Maegdefessel L., Linde T., Krapiec F., Hamilton K., Steinseifer U., van Ryn J., et al. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves. Thromb Res 2010, 126:e196-e200.
8. McKellar S.H., Abel S., Camp C.L., Suri R.M., Ereth M.H., Schaff H.V. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg 2011, 141:1410-1416.